istesso.co.uk Open in urlscan Pro
78.141.198.232  Public Scan

Submitted URL: http://istesso.co.uk/
Effective URL: https://istesso.co.uk/
Submission: On January 30 via api from US — Scanned from GB

Form analysis 0 forms found in the DOM

Text Content

 * Home
 * About
 * Science
 * Pipeline
 * News & Press
 * Policies
 * Contact

Your browser does not support the video tag.


FINDING NATURE’S RHYTHM


A NEW HORIZON FOR AUTOIMMUNITY.



Istesso is at the forefront of an emerging field of science called
immunometabolism. Our pioneering work has the potential to revolutionise the
treatment of autoimmunity and, as a result, improve the lives of millions around
the world.

We develop novel treatments for unmet needs in autoimmunity. Our groundbreaking
products work by reprogramming cellular metabolism and have applications in
autoimmune conditions such as rheumatoid arthritis and multiple sclerosis, as
well as cancer.

Read More




PIPELINE

Our pipeline consists of drugs that reprogram metabolism in target immune cells,
thereby offering novel treatments for autoimmune conditions. We are at the most
exciting stage of development of our first-in-class pipeline…


MBS2320

Rheumatoid arthritis
Discovery Pre-clinical Phase 1 Phase 2 Phase 3



MBS2612

Autoimmune, neuroprotection/fibrosis
Discovery Pre-clinical Phase 1 Phase 2 Phase 3



IST003

Autoimmune, neuroprotection/fibrosis
Discovery Pre-clinical Phase 1 Phase 2 Phase 3

Read More

"It’s hard to imagine anything more rewarding than translating exciting science
into treatments with the potential to benefit patients."

Lisa Patel

Chief Executive Officer


LATEST NEWS


ISTESSO ANNOUNCES FDA FAST TRACK AND ORPHAN DRUG DESIGNATION FOR MBS2320

Istesso Limited, the immunometabolism drug discovery and development company,
today...

5th December 2022


CEO LISA PATEL ON CAREERS IN DISCOVERY

Our CEO Lisa Patel was recently featured on Tom Froggatt’s...

30th November 2022


MBS2320 ADMINISTERED TO PARTICIPANTS WITH MODERATE-TO-SEVERE RHEUMATOID
ARTHRITIS

Istesso Limited, the immunometabolism drug discovery and development company,
today...

6th September 2022
More news

 * Linkedin
 * Twitter

 * Privacy Policy
 * Cookie Policy

Site by Lolly Agency

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in
settings.

Accept Reject
Change cookie settings
Close GDPR Cookie Settings
 * Privacy Overview
 * Strictly Necessary Cookies
 * 3rd Party Cookies
 * Cookie Policy


Privacy Overview

This website uses cookies so that we can provide you with the best user
experience possible. Cookie information is stored in your browser and performs
functions such as recognising you when you return to our website and helping our
team to understand which sections of the website you find most interesting and
useful.

More information about our Privacy Policy

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save
your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This
means that every time you visit this website you will need to enable or disable
cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the
number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your
preferences!

Cookie Policy

More information about our Cookie Policy

Enable All Save Changes